<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Elevated Intraocular Pressure Associated with Retinal Procedures - EyeWiki</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"mdy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"ZAVjVrydbNjqe1d87p-WawAAAAQ","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures","wgTitle":"Elevated Intraocular Pressure Associated with Retinal Procedures","wgCurRevisionId":87673,"wgRevisionId":87673,"wgArticleId":1199,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgCategories":["Articles","Glaucoma"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures","wgRelevantArticleId":1199,
"wgIsProbablyEditable":!1,"wgRelevantPageIsProbablyEditable":!1,"wgRestrictionEdit":[],"wgRestrictionMove":[],"sdgDownArrowImage":"/w/extensions/SemanticDrilldown/skins/down-arrow.png","sdgRightArrowImage":"/w/extensions/SemanticDrilldown/skins/right-arrow.png","wgCiteDrawerEnableDesktop":!1,"wgCiteDrawerEnableMobile":!0,"wgCiteDrawerTheme":"dark","wgPageFormsTargetName":null,"wgPageFormsAutocompleteValues":[],"wgPageFormsAutocompleteOnAllChars":!1,"wgPageFormsFieldProperties":[],"wgPageFormsCargoFields":[],"wgPageFormsDependentFields":[],"wgPageFormsCalendarValues":[],"wgPageFormsCalendarParams":[],"wgPageFormsCalendarHTML":null,"wgPageFormsGridValues":[],"wgPageFormsGridParams":[],"wgPageFormsContLangYes":null,"wgPageFormsContLangNo":null,"wgPageFormsContLangMonths":[],"wgPageFormsHeightForMinimizingInstances":800,"wgPageFormsShowOnSelect":[],"wgPageFormsScriptPath":"/w/extensions/PageForms","edgValues":[],"wgPageFormsEDSettings":null,"wgAmericanDates":!0,
"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"srfFilteredConfig":null,"wgEditSubmitButtonLabelPublish":!1};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","mediawiki.ui.button":"ready","skins.chameleon":"ready","zzz.ext.bootstrap.styles":"ready","mediawiki.toc.styles":"ready","ext.CookieWarning.styles":"ready","oojs-ui-core.styles":"ready","oojs-ui.styles.indicators":"ready","mediawiki.widgets.styles":"ready","oojs-ui-core.icons":"ready","ext.visualEditor.desktopArticleTarget.noscript":"ready","ext.srf.styles":"ready","ext.smw.style":"ready","ext.smw.tooltip.styles":"ready"};RLPAGEMODULES=["ext.smw.style","ext.smw.tooltips","ext.cite.ux-enhancements","smw.entityexaminer","site","mediawiki.page.startup","mediawiki.page.ready","mediawiki.toc","ext.citedrawer.main","ext.CookieWarning","ext.visualEditor.desktopArticleTarget.init",
"ext.visualEditor.targetLoader","ext.eyeWiki","ext.eyeWiki.slideshow","sentry.init","ext.bootstrap.scripts"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.CookieWarning.styles%7Cext.cite.styles%7Cext.visualEditor.desktopArticleTarget.noscript%7Cmediawiki.toc.styles%7Cmediawiki.ui.button%7Cmediawiki.widgets.styles%7Coojs-ui-core.icons%2Cstyles%7Coojs-ui.styles.indicators%7Cskins.chameleon%7Czzz.ext.bootstrap.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.smw.style%7Cext.smw.tooltip.styles&amp;only=styles&amp;skin=chameleon"/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.srf.styles&amp;only=styles&amp;skin=chameleon"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=chameleon"></script>
<style>#mw-indicator-mw-helplink {display:none;}</style>
<meta name="ResourceLoaderDynamicStyles" content=""/>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=site.styles&amp;only=styles&amp;skin=chameleon"/>
<meta name="generator" content="MediaWiki 1.35.8"/>
<meta name="description" content="Secondary glaucoma can occur after various vitreoretinal procedures&amp;#91;1&amp;#93; &amp;#91;2&amp;#93;. The risk factors vary for each type of procedure, and are of particular importance for the follow-up management of patients who may be predisposed to elevation of intraocular pressure (IOP). The pathophysiology can be either due to open-angle&amp;#91;1&amp;#93;&amp;#91;3&amp;#93;, closed-angle mechanisms&amp;#91;1&amp;#93;&amp;#91;3&amp;#93;&amp;#91;4&amp;#93;, or both&amp;#91;1&amp;#93;&amp;#91;3&amp;#93;, which can heavily influence the management of secondary IOP elevation. This article provides a summary of the incidence, risk factors, pathophysiology, as well as management of elevated IOP following selected vitreous and retinal procedures."/>
<meta name="date" content="2022-12-24"/>
<meta name="WT.seg_1" content="0"/>
<meta name="google-site-verification" content="mtQvMIGqpWB4oyYM5mux15MHU-3qWI0bWtyRa2b5rlk"/>
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"/>
<link rel="alternate" type="application/rdf+xml" title="Elevated Intraocular Pressure Associated with Retinal Procedures" href="/w/index.php?title=Special:ExportRDF/Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures&amp;xmlmime=rdf"/>
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="EyeWiki (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="https://eyewiki.org/w/api.php?action=rsd"/>
<link rel="preconnect" href="https://fonts.gstatic.com">
<link href="https://fonts.googleapis.com/css2?family=Lato:ital,wght@0,400;0,700;1,400&display=swap" rel="stylesheet">
<!-- Favicons MEYE-108 -->
<link rel="apple-touch-icon" sizes="120x120" href="/w/extensions/EyeWiki/favicons/apple-touch-icon.png">
<link rel="icon" type="image/png" sizes="32x32" href="/w/extensions/EyeWiki/favicons/favicon-32x32.png">
<link rel="icon" type="image/png" sizes="16x16" href="/w/extensions/EyeWiki/favicons/favicon-16x16.png">
<link rel="manifest" href="/w/extensions/EyeWiki/favicons/site.webmanifest">
<link rel="mask-icon" href="/w/extensions/EyeWiki/favicons/safari-pinned-tab.svg" color="#603cba">
<link rel="shortcut icon" href="/w/extensions/EyeWiki/favicons/favicon.ico">
<meta name="msapplication-TileColor" content="#603cba">
<meta name="msapplication-config" content="/w/extensions/EyeWiki/favicons/browserconfig.xml">
<meta name="theme-color" content="#ffffff">
<script> window.interdeal = { "sitekey": "81c701489fb8bb4ab90ca1cb0931f9c5", "Position": "Left", "Menulang": "EN", "domains": { "js": "https://cdn.equalweb.com/", "acc": "https://access.equalweb.com/" }, "btnStyle": { "vPosition": [ "80%", null ], "scale": [ "0.8", "0.8" ], "color": { "main": "#1876c9" }, "icon": { "type": 1, "outline": false } } }; (function(doc, head, body){ var coreCall = doc.createElement('script'); coreCall.src = 'https://cdn.equalweb.com/core/4.3.8/accessibility.js'; coreCall.defer = true; coreCall.integrity = 'sha512-u6i35wNTfRZXp0KDwSb3TntaIKI2ItCt/H/KcYIsBeVbaVMerEQLBnU5/ztfBg9aSW1gg7AN4CqCu9a455jkUg=='; coreCall.crossOrigin = 'anonymous'; coreCall.setAttribute('data-cfasync', true ); body? body.appendChild(coreCall) : head.appendChild(coreCall); })(document, document.head, document.body); </script>
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures rootpage-Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures layout-standard skin-chameleon action-view">
	<div class="flex-fill container">
		<div class="row">
			<div class="flex-grow-0 col-12 col-cmln-6 d-flex flex-column flex-md-row w-md-100 justify-content-start align-items-center col">
					<div class="float-left mr-3 mb-2"><a href="//aao.org"><img id="aao-logo" src="/w/extensions/EyeWiki/skins/chameleon/AAO_Logo.png"></a></div>
                		
				<!-- logo and main page link -->
				<div id="p-logo" class="p-logo" role="banner">
					<a href="/Main_Page" title="Visit the main page"><img src="/w/extensions/EyeWiki/skins/chameleon/EyeWiki_Logo.png" alt="EyeWiki"/></a>
				</div>
			</div>
			<div class="ml-auto col-12 col-cmln col">
				<div class="row">
					<div class="col">
						<!-- personal tools -->
						<div class="p-personal pull-right" id="p-personal" >
							<ul class="p-personal-tools" >
								<li id="pt-createaccount"><a href="/w/index.php?title=Special:CreateAccount&amp;returnto=Elevated+Intraocular+Pressure+Associated+with+Retinal+Procedures" title="You are encouraged to create an account and log in; however, it is not mandatory" class="pt-createaccount">Create account</a></li>
								<li id="pt-login"><a href="/w/index.php?title=Special:UserLogin&amp;returnto=Elevated+Intraocular+Pressure+Associated+with+Retinal+Procedures" title="You are encouraged to log in; however, it is not mandatory [o]" accesskey="o" class="pt-login">Log in</a></li>
							</ul>
						</div>

					</div>
				</div>
				<div class="row">
					<div class="col">
						<!-- search form -->
						<div  id="p-search" class="p-search pull-right" role="search"  >
							<form  id="searchform" class="mw-search" action="/w/index.php" >
								<input type="hidden" name="title" value=" Special:Search" />
								<div class="input-group">
									<input name="search" placeholder="Search EyeWiki" title="Search EyeWiki [f]" accesskey="f" id="searchInput" class="form-control"/>
									<div class="input-group-append">
										<button value="Go" id="searchGoButton" name="go" type="submit" class="search-btn searchGoButton" aria-label="Go to page" title="Go to a page with this exact name if it exists"></button>
									</div>
								</div>
							</form>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar collapsible mb-3 mt-2 p-1 mt-cmln-0" role="navigation" id="mw-navigation">
					<button type="button" class="navbar-toggler" data-toggle="collapse" data-target="#hbpzyttr2z"></button>
					<div class="collapse navbar-collapse hbpzyttr2z" id="hbpzyttr2z">
						<div class="navbar-nav"><div class="nav-item"><a class="nav-link fas fa-home"  href="/Main_Page">Main Page</a></div><div class="nav-item"><a class="nav-link fas fa-book"  href="/Category:Articles">Articles</a></div><div class="nav-item"><a class="nav-link fas fa-play"  href="/Help:Getting_Started">Getting Started</a></div><div class="nav-item"><a class="nav-link fas fa-question"  href="/Help:Contents">Help</a></div><div class="nav-item"><a class="nav-link fas fa-backward"  href="/Special:RecentChanges">Recent changes</a></div><div class="nav-item"><a class="nav-link fas fa-door-open"  href="#">My Portal</a></div>
						</div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- Content navigation -->
				<div class="mb-3 pagetools p-contentnavigation" id="p-contentnavigation">
					<!-- namespaces -->
					<div id="p-namespaces" class="p-namespaces">
						<div class="tab-group">
							<div id="ca-nstab-main" class="selected"><a href="/Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures" title="View the content page [c]" accesskey="c" class="selected ca-nstab-main">Page</a></div>
							<div id="ca-talk"><a href="/Talk:Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures" rel="discussion" title="Discussion about the content page [t]" accesskey="t" class="ca-talk">Discussion</a></div>
						</div>
					</div>
					<!-- views -->
					<div id="p-views" class="p-views">
						<div class="tab-group">
							<div id="ca-formedit"><a href="/w/index.php?title=Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures&amp;action=formedit" title="Edit this page with a form [&amp;]" accesskey="&amp;" class="ca-formedit">View form</a></div>
							<div id="ca-viewsource"><a href="/w/index.php?title=Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures&amp;action=edit" title="This page is protected.&#10;You can view its source [e]" accesskey="e" class="ca-viewsource">View source</a></div>
							<div id="ca-history"><a href="/w/index.php?title=Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures&amp;action=history" title="Past revisions of this page [h]" accesskey="h" class="ca-history">History</a></div>
						</div>
					</div>
				</div>
			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">

			</div>
		</div>
		<div class="row">
			<div class="col-auto mx-auto col">
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- start the content area -->
				<div id="content" class="mw-body content"><a id="top" class="top"></a>
					<div id="mw-indicators" class="mw-indicators">
					<div id="mw-indicator-smw-entity-examiner" class="mw-indicator mw-indicator-smw-entity-examiner"><div class="smw-entity-examiner smw-indicator-vertical-bar-loader" data-subject="Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures#0##" data-dir="ltr" data-uselang="" title="Running an examiner in the background"></div></div>
				</div>
						<div class="contentHeader">
						<!-- title of the page -->
						<h1 id="firstHeading" class="firstHeading">Elevated Intraocular Pressure Associated with Retinal Procedures</h1>
						<!-- tagline; usually goes something like "From WikiName" primary purpose of this seems to be for printing to identify the source of the content -->
						<div id="siteSub" class="siteSub">From EyeWiki</div><div id="jump-to-nav" class="mw-jump jump-to-nav">Jump to:<a href="#mw-navigation">navigation</a>, <a href="#p-search">search</a></div>
					</div>
					<div id="bodyContent" class="bodyContent">
						<!-- body text -->

						<div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><div class="mw-parser-output"><div id="article-header" data-description2-ignore=""><div id="contest" style="margin-bottom: 6px;">
</div>
<div class="infobox contributors">
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header"><a href="/Property:Authors" title="Property:Authors">Article initiated by</a>:
</div>
<div class="info-section-body"><a href="/User:Babak.Eliassi-Rad" title="User:Babak.Eliassi-Rad">Babak Eliassi-Rad, MD</a>,&#8201;<a href="/w/index.php?title=User:Ingrid_Chang&amp;action=formedit&amp;redlink=1" class="new" title="User:Ingrid Chang (page does not exist)">Ingrid Chang</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">All authors and contributors:
</div>
<div class="info-section-body"> <a href="/User:Jody.R.Piltz.SEC" title="User:Jody.R.Piltz.SEC">Jody Piltz-Seymour, M.D.</a>,&#160;<a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a>,&#160;<a href="/User:Babak.Eliassi-Rad" title="User:Babak.Eliassi-Rad">Babak Eliassi-Rad, MD</a>
</div>
</div>
<div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Assigned editor:
</div>
<div class="info-section-body"> <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a></div>
</div><div class="info-section" style="margin-bottom: 10px;">
<div class="info-section-header">Review:
</div>
<div class="info-section-body">Assigned status <b>Up to Date</b>
</div>
</div>&#160;by <a href="/User:Ahmad.A.Aref" title="User:Ahmad.A.Aref">Ahmad A. Aref, MD, MBA</a> on December 25, 2022.
</div>
<div style="display:none;">
<table cellspacing="5">

<tbody><tr>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures&amp;action=formedit">add</a></small>
</td></tr>
<tr>
<th align="right"><b><a href="/Property:Contributing_Editors" title="Property:Contributing Editors">Contributing Editors</a>:</b>
</th>
<td><small><a rel="nofollow" class="external text" href="https://eyewiki.org/w/index.php?title=Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures&amp;action=formedit">add</a></small>
</td></tr>
</tbody></table></div>
<div style="display:none;">
<p><br />
</p>
</div>
<div id="local-videos">
</div>
</div>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none" /><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul>
<li class="toclevel-1 tocsection-1"><a href="#Introduction"><span class="tocnumber">1</span> <span class="toctext">Introduction</span></a></li>
<li class="toclevel-1 tocsection-2"><a href="#Glaucoma_following_pars_plana_vitrectomy_.28PPV.29"><span class="tocnumber">2</span> <span class="toctext">Glaucoma following pars plana vitrectomy (PPV)</span></a>
<ul>
<li class="toclevel-2 tocsection-3"><a href="#Incidence"><span class="tocnumber">2.1</span> <span class="toctext">Incidence</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Risk_factors"><span class="tocnumber">2.2</span> <span class="toctext">Risk factors</span></a></li>
<li class="toclevel-2 tocsection-5"><a href="#Pathophysiology"><span class="tocnumber">2.3</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-2 tocsection-6"><a href="#Management"><span class="tocnumber">2.4</span> <span class="toctext">Management</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-7"><a href="#Glaucoma_following_scleral_buckle_procedure"><span class="tocnumber">3</span> <span class="toctext">Glaucoma following scleral buckle procedure</span></a>
<ul>
<li class="toclevel-2 tocsection-8"><a href="#Incidence_2"><span class="tocnumber">3.1</span> <span class="toctext">Incidence</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#Risk_factors_2"><span class="tocnumber">3.2</span> <span class="toctext">Risk factors</span></a></li>
<li class="toclevel-2 tocsection-10"><a href="#Pathophysiology_2"><span class="tocnumber">3.3</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-2 tocsection-11"><a href="#Management_2"><span class="tocnumber">3.4</span> <span class="toctext">Management</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-12"><a href="#Glaucoma_following_panretinal_photocoagulation_.28PRP.29"><span class="tocnumber">4</span> <span class="toctext">Glaucoma following panretinal photocoagulation (PRP)</span></a>
<ul>
<li class="toclevel-2 tocsection-13"><a href="#Incidence_3"><span class="tocnumber">4.1</span> <span class="toctext">Incidence</span></a></li>
<li class="toclevel-2 tocsection-14"><a href="#Risk_factors_3"><span class="tocnumber">4.2</span> <span class="toctext">Risk factors</span></a></li>
<li class="toclevel-2 tocsection-15"><a href="#Pathophysiology_3"><span class="tocnumber">4.3</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-2 tocsection-16"><a href="#Management_3"><span class="tocnumber">4.4</span> <span class="toctext">Management</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-17"><a href="#Glaucoma_following_intravitreal_anti_vascular_endothelial_growth_factor"><span class="tocnumber">5</span> <span class="toctext">Glaucoma following intravitreal anti vascular endothelial growth factor</span></a>
<ul>
<li class="toclevel-2 tocsection-18"><a href="#Incidence_4"><span class="tocnumber">5.1</span> <span class="toctext">Incidence</span></a></li>
<li class="toclevel-2 tocsection-19"><a href="#Risk_factors_4"><span class="tocnumber">5.2</span> <span class="toctext">Risk factors</span></a></li>
<li class="toclevel-2 tocsection-20"><a href="#Pathophysiology_4"><span class="tocnumber">5.3</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-2 tocsection-21"><a href="#Management_4"><span class="tocnumber">5.4</span> <span class="toctext">Management</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-22"><a href="#Glaucoma_following_intravitreal_triamcinolone_acetonide_injection_.28IVTA.29:"><span class="tocnumber">6</span> <span class="toctext">Glaucoma following intravitreal triamcinolone acetonide injection (IVTA):</span></a>
<ul>
<li class="toclevel-2 tocsection-23"><a href="#Incidence_5"><span class="tocnumber">6.1</span> <span class="toctext">Incidence</span></a></li>
<li class="toclevel-2 tocsection-24"><a href="#Risk_factors_5"><span class="tocnumber">6.2</span> <span class="toctext">Risk factors</span></a></li>
<li class="toclevel-2 tocsection-25"><a href="#Pathophysiology_5"><span class="tocnumber">6.3</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-2 tocsection-26"><a href="#Management_5"><span class="tocnumber">6.4</span> <span class="toctext">Management</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-27"><a href="#Glaucoma_following_use_of_silicone_oil"><span class="tocnumber">7</span> <span class="toctext">Glaucoma following use of silicone oil</span></a>
<ul>
<li class="toclevel-2 tocsection-28"><a href="#Incidence_6"><span class="tocnumber">7.1</span> <span class="toctext">Incidence</span></a></li>
<li class="toclevel-2 tocsection-29"><a href="#Risk_factors_6"><span class="tocnumber">7.2</span> <span class="toctext">Risk factors</span></a></li>
<li class="toclevel-2 tocsection-30"><a href="#Pathophysiology_6"><span class="tocnumber">7.3</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-2 tocsection-31"><a href="#Management_6"><span class="tocnumber">7.4</span> <span class="toctext">Management</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-32"><a href="#Glaucoma_following_intravitreal_gas"><span class="tocnumber">8</span> <span class="toctext">Glaucoma following intravitreal gas</span></a>
<ul>
<li class="toclevel-2 tocsection-33"><a href="#Incidence_7"><span class="tocnumber">8.1</span> <span class="toctext">Incidence</span></a></li>
<li class="toclevel-2 tocsection-34"><a href="#Risk_factors_7"><span class="tocnumber">8.2</span> <span class="toctext">Risk factors</span></a></li>
<li class="toclevel-2 tocsection-35"><a href="#Pathophysiology_7"><span class="tocnumber">8.3</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-2 tocsection-36"><a href="#Management_7"><span class="tocnumber">8.4</span> <span class="toctext">Management</span></a></li>
</ul>
</li>
<li class="toclevel-1 tocsection-37"><a href="#Conclusion"><span class="tocnumber">9</span> <span class="toctext">Conclusion</span></a></li>
<li class="toclevel-1 tocsection-38"><a href="#Additional_Resources"><span class="tocnumber">10</span> <span class="toctext">Additional Resources</span></a></li>
<li class="toclevel-1 tocsection-39"><a href="#References"><span class="tocnumber">11</span> <span class="toctext">References</span></a></li>
</ul>
</div>

<h1><span class="mw-headline" id="Introduction">Introduction</span></h1>
<p>Secondary glaucoma can occur after various vitreoretinal procedures<sup id="cite_ref-costarides1_1-0" class="reference"><a href="#cite_note-costarides1-1">&#91;1&#93;</a></sup> <sup id="cite_ref-gedde2_2-0" class="reference"><a href="#cite_note-gedde2-2">&#91;2&#93;</a></sup>. The risk factors vary for each type of procedure, and are of particular importance for the follow-up management of patients who may be predisposed to elevation of intraocular pressure (IOP). The pathophysiology can be either due to open-angle<sup id="cite_ref-costarides1_1-1" class="reference"><a href="#cite_note-costarides1-1">&#91;1&#93;</a></sup><sup id="cite_ref-han3_3-0" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup>, closed-angle mechanisms<sup id="cite_ref-costarides1_1-2" class="reference"><a href="#cite_note-costarides1-1">&#91;1&#93;</a></sup><sup id="cite_ref-han3_3-1" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup><sup id="cite_ref-ichhpujani4_4-0" class="reference"><a href="#cite_note-ichhpujani4-4">&#91;4&#93;</a></sup>, or both<sup id="cite_ref-costarides1_1-3" class="reference"><a href="#cite_note-costarides1-1">&#91;1&#93;</a></sup><sup id="cite_ref-han3_3-2" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup>, which can heavily influence the management of secondary IOP elevation. This article provides a summary of the incidence, risk factors, pathophysiology, as well as management of elevated IOP following selected vitreous and retinal procedures.
</p>
<h1><span id="Glaucoma_following_pars_plana_vitrectomy_(PPV)"></span><span class="mw-headline" id="Glaucoma_following_pars_plana_vitrectomy_.28PPV.29">Glaucoma following pars plana vitrectomy (PPV)</span></h1>
<h2><span class="mw-headline" id="Incidence">Incidence</span></h2>
<p>Elevated IOP is a common complication following pars plana vitrectomy<sup id="cite_ref-han3_3-3" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup>. The reported frequency of post-vitrectomy glaucoma from studies done in 1970 and 1980s ranges from 20-60%<sup id="cite_ref-han3_3-4" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup><sup id="cite_ref-faulborn5_5-0" class="reference"><a href="#cite_note-faulborn5-5">&#91;5&#93;</a></sup> <sup id="cite_ref-aaberg6_6-0" class="reference"><a href="#cite_note-aaberg6-6">&#91;6&#93;</a></sup> <sup id="cite_ref-ghartey7_7-0" class="reference"><a href="#cite_note-ghartey7-7">&#91;7&#93;</a></sup>. In a prospective study, Han et al<sup id="cite_ref-han3_3-5" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup> found that approximately 60% of patients had an acute IOP rise of 5-22 mg Hg within 48 hours of PPV and approximately 36% of patients had an acute IOP rise of &gt; 30 mmHg; there was no significant difference between preoperative and late postoperative IOP. In a recent retrospective cohort study of 111 eyes with a mean follow up of 49 months, there was no long-term increase in IOP following pars plana vitrectomy<sup id="cite_ref-lalezary8_8-0" class="reference"><a href="#cite_note-lalezary8-8">&#91;8&#93;</a></sup>.&#160;However, a more recent population-based study found a significantly greater 10-year cumulative probability of developing glaucoma in patients undergoing scleral buckle with vitrectomy or vitrectomy alone (8.9%, 95% confidence interval, 3.8%-14% vs. 1.0%, 95% confidence interval 0-2.4%; P=0.02).<sup id="cite_ref-9" class="reference"><a href="#cite_note-9">&#91;9&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Risk_factors">Risk factors</span></h2>
<p>There are several variables that are associated with an increased risk of acute IOP elevation following pars plana vitrectomy; these include: combined scleral buckle and PPV, intraoperative scatter endophotocoagulation, and/or pars plana lensectomy performed at the same time as pars plana vitrectomy<sup id="cite_ref-han3_3-6" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup>. Fibrin formation after PPV also increases the risk of secondary glaucoma<sup id="cite_ref-han3_3-7" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup>. In addition, patients undergoing pars plana vitrectomy for proliferative vitreoretinopathy are more likely to experience postoperative IOP elevation compared to those undergoing the procedure for macular hole repair<sup id="cite_ref-han3_3-8" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Pathophysiology">Pathophysiology</span></h2>
<p>Secondary open-angle glaucoma (OAG) accounts for the majority of postvitrectomy glaucoma, with angle closure mechanisms accounting for approximately 20% of cases<sup id="cite_ref-han3_3-9" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup>. OAG is caused by: gas expansion without angle closure, inflammation, silicone oil without pupillary block, corticosteroid response, and blood-mediated mechanisms<sup id="cite_ref-ichhpujani4_4-1" class="reference"><a href="#cite_note-ichhpujani4-4">&#91;4&#93;</a></sup>. Angle closure mechanisms include pupillary block mediated by intraocular gas, silicone oil, fibrin or intraocular lens as well as ciliary body edema and iridocorneal apposition<sup id="cite_ref-han3_3-10" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Management">Management</span></h2>
<p>The majority of patients without a previous history of ocular hypertension or glaucoma can tolerate a transient postoperative rise in IOP, with no evident effect on visual function<sup id="cite_ref-tranos9_10-0" class="reference"><a href="#cite_note-tranos9-10">&#91;10&#93;</a></sup>. If therapy is needed to control IOP elevation, most cases can be managed medically with antiglaucoma medications<sup id="cite_ref-costarides1_1-4" class="reference"><a href="#cite_note-costarides1-1">&#91;1&#93;</a></sup> or by tapping gas from the posterior segment in cases of overfill. Occasionally, surgical intervention is needed to relieve extremely high IOPs, and the procedure is chosen carefully based on the mechanism of IOP elevation. Han et al.<sup id="cite_ref-han3_3-11" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup> showed that 11% of the patients in their study required some form of surgical intervention which included anterior chamber paracentesis, laser iridotomy, laser iridoplasty and laser membranectomy; none of their patients required a trabeculectomy or placement of glaucoma drainage device. In cases of postoperative fibrin pupillary block, argon laser has been used to create holes in the fibrin pupillary membrane<sup id="cite_ref-lewis10_11-0" class="reference"><a href="#cite_note-lewis10-11">&#91;11&#93;</a></sup>, and intrecameral injection of recombinant tissue plasminogen activator has been successfully used to dissolve the fibrin clot<sup id="cite_ref-jaffe11_12-0" class="reference"><a href="#cite_note-jaffe11-12">&#91;12&#93;</a></sup>.&#160;&#160; 
</p>
<h1><span class="mw-headline" id="Glaucoma_following_scleral_buckle_procedure">Glaucoma following scleral buckle procedure</span></h1>
<h2><span class="mw-headline" id="Incidence_2">Incidence</span></h2>
<p>The occurrence of angle-closure glaucoma following scleral buckle is estimated to be 1.4% to 4.4%<sup id="cite_ref-sebestyen12_13-0" class="reference"><a href="#cite_note-sebestyen12-13">&#91;13&#93;</a></sup><sup id="cite_ref-perez13_14-0" class="reference"><a href="#cite_note-perez13-14">&#91;14&#93;</a></sup>. However, the incidence of shallowing of the anterior chamber without angle closure has been reported to be significantly higher, ranging from 14.4% to 50%<sup id="cite_ref-hartley14_15-0" class="reference"><a href="#cite_note-hartley14-15">&#91;15&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Risk_factors_2">Risk factors</span></h2>
<p>Predisposing factors for angle closure glaucoma following scleral buckling procedures include pre-existing narrow angles, use of an encircling band, placement of encircling band anterior to the equator, high myopia, older patient age, and postoperative ciliochoroidal detachment<sup id="cite_ref-gedde2_2-1" class="reference"><a href="#cite_note-gedde2-2">&#91;2&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Pathophysiology_2">Pathophysiology</span></h2>
<p>The mechanism behind angle closure after scleral buckling has been shown experimentally in animal models. Placement of scleral buckle causes impaired venous drainage from the vortex veins, leading to congestion and swelling of the ciliary body<sup id="cite_ref-gedde2_2-2" class="reference"><a href="#cite_note-gedde2-2">&#91;2&#93;</a></sup>. The edematous ciliary body is displaced anteriorly about the sclera spur, and shifts the lens-iris diaphragm forward resulting in angle closure<sup id="cite_ref-gedde2_2-3" class="reference"><a href="#cite_note-gedde2-2">&#91;2&#93;</a></sup>.  
</p>
<h2><span class="mw-headline" id="Management_2">Management</span></h2>
<p>In most cases, secondary angle-closure glaucoma resolves spontaneously within several weeks. Medical therapy includes cycloplegics, corticosteroids and aqueous suppressants<sup id="cite_ref-gedde2_2-4" class="reference"><a href="#cite_note-gedde2-2">&#91;2&#93;</a></sup>. Laser iridoplasty may be beneficial in cases refractory to medical treatment by opening the angle and facilitating aqueous outflow. Laser iridotomy, however, is rarely helpful because pupillary block is not the primary mechanism of angle closure following scleral buckling<sup id="cite_ref-gedde2_2-5" class="reference"><a href="#cite_note-gedde2-2">&#91;2&#93;</a></sup>. Trabeculectomy may be technically difficult due to conjunctival scarring from previous retinal surgery. In a retrospective study, Sidoti et al.<sup id="cite_ref-sidoti15_16-0" class="reference"><a href="#cite_note-sidoti15-16">&#91;16&#93;</a></sup> found that aqueous tube shunts achieved IOP control (defined as final IOP between 6-21 mmHg) in 85% of patients with a follow-up of 19.1-45.5 months. 
</p>
<h1><span id="Glaucoma_following_panretinal_photocoagulation_(PRP)"></span><span class="mw-headline" id="Glaucoma_following_panretinal_photocoagulation_.28PRP.29">Glaucoma following panretinal photocoagulation (PRP)</span></h1>
<h2><span class="mw-headline" id="Incidence_3">Incidence</span></h2>
<p>Transient increases in intraocular pressure following PRP is quite common, with 32% to 94% of patients experiencing an increase in IOP of <u>&gt;</u> 6 mm Hg<sup id="cite_ref-tsai16_17-0" class="reference"><a href="#cite_note-tsai16-17">&#91;17&#93;</a></sup> <sup id="cite_ref-blondeau17_18-0" class="reference"><a href="#cite_note-blondeau17-18">&#91;18&#93;</a></sup>. The IOP spikes usually occur immediately following retinal photocoagulation; in a study by Blondeau et al.<sup id="cite_ref-tsai16_17-1" class="reference"><a href="#cite_note-tsai16-17">&#91;17&#93;</a></sup>, all cases of PRP-related ocular hypertension were detected within 2 hours after laser treatment. 
</p>
<h2><span class="mw-headline" id="Risk_factors_3">Risk factors</span></h2>
<p>The risk factors have not been well studied however it appears that the amount of laser energy may influence the incidence and severity of pressure elevations16.<sup id="cite_ref-tsai16_17-2" class="reference"><a href="#cite_note-tsai16-17">&#91;17&#93;</a></sup> Tsai et al.<sup id="cite_ref-tsai16_17-3" class="reference"><a href="#cite_note-tsai16-17">&#91;17&#93;</a></sup> hypothesized that lower  laser energy levels may be associated with decreased incidence and severity of IOP elevation following PRP. In addition, neither age nor the type of diabetes influences the incidence<sup id="cite_ref-blondeau17_18-1" class="reference"><a href="#cite_note-blondeau17-18">&#91;18&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Pathophysiology_3">Pathophysiology</span></h2>
<p>IOP elevation after PRP may result from open or closed angle mechanisms.&#160; Proposed open angle mechanisms include: aqueous outflow blockage due to compression of episcleral veins by the flanges of the fundus contact lens used in delivering the photocoagulation treatment; movement of fluid from choroid into the vitreous secondary to breakdown of blood-retinal barrier; decreased uveoscleral outflow from congestion of the ciliary body; laser damage to the short ciliary nerves causing decreased ciliary muscle tone, as well as release of prostaglandins<sup id="cite_ref-blondeau17_18-2" class="reference"><a href="#cite_note-blondeau17-18">&#91;18&#93;</a></sup>. The pathogenesis behind closed-angle is thought to be due to swelling of the ciliary body or movement of fluid from the choroid into the vitreous secondary to a temporary weakening of the blood-retinal barrier, both of which can lead to anterior displacement of lens-iris diaphragm<sup id="cite_ref-blondeau17_18-3" class="reference"><a href="#cite_note-blondeau17-18">&#91;18&#93;</a></sup>
</p>
<h2><span class="mw-headline" id="Management_3">Management</span></h2>
<p>The IOP elevation is usually transient with most cases resolving within 1 month. Pretreatment with apralonidine has been shown to reduce the incidence of IOP elevation following laser surgery as compared to placebo (25% vs 32%), however the difference was not statistically significant<sup id="cite_ref-tsai16_17-4" class="reference"><a href="#cite_note-tsai16-17">&#91;17&#93;</a></sup>. IOP elevation following PRP can usually be managed medically by topical medications such as cycloplegics and aqueous suppressants. 
</p>
<h1><span class="mw-headline" id="Glaucoma_following_intravitreal_anti_vascular_endothelial_growth_factor">Glaucoma following intravitreal anti vascular endothelial growth factor</span></h1>
<h2><span class="mw-headline" id="Incidence_4">Incidence</span></h2>
<p>Use of intravitreal anti-vascular endothelial growth factor (anti-VEGF) agents such as ranibizumab (Lucentis) and bevacizumab (Avastin) can lead to acute and/or chronic elevation of IOP. The incidence of sustained IOP elevations has been reported to range from 3.45% to 6%, and appears to be related the frequency of intravitreal anti-VEGF injections<sup id="cite_ref-adelman18_19-0" class="reference"><a href="#cite_note-adelman18-19">&#91;19&#93;</a></sup> <sup id="cite_ref-good19_20-0" class="reference"><a href="#cite_note-good19-20">&#91;20&#93;</a></sup><sup id="cite_ref-tseng20_21-0" class="reference"><a href="#cite_note-tseng20-21">&#91;21&#93;</a></sup>.  In a prospective trial of 312 patients with macular edema related to retinal vein occlusion and treated with anti-VEGF therapy, 8% experienced an IOP elevation more than 10 mmHg over baseline and 1.6% experienced an IOP higher than 35 mmHg by 60 months of follow-up.<sup id="cite_ref-22" class="reference"><a href="#cite_note-22">&#91;22&#93;</a></sup>  
</p>
<h2><span class="mw-headline" id="Risk_factors_4">Risk factors</span></h2>
<p>The risk factors for ocular hypertension following intravitreal anti-VEGF have not been well documented. Good et al.<sup id="cite_ref-good19_20-1" class="reference"><a href="#cite_note-good19-20">&#91;20&#93;</a></sup> has found a higher prevalence of eyes with IOP elevations after receiving only bevacizumab (9.9%) as compared with those only receiving ranibizumab (3.1%), as well as higher prevelance in patients with preexisting glaucoma compared with eyes without preexisting glaucoma. In addition, the incidence of sustained IOP elevation appears to be related to the frequency of intravitreal anti-VEGF as lower frequencies of anti-VEGF treatment may reduce the risk of further IOP elevation<sup id="cite_ref-tseng20_21-1" class="reference"><a href="#cite_note-tseng20-21">&#91;21&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Pathophysiology_4">Pathophysiology</span></h2>
<p>The mechanism in which intravitreal anti-VEGF therapy contributes to IOP elevation is not clear; however there have been several proposed mechanisms. Immediate rise in IOP may be related to the volume of fluid introduced into the vitreous cavity via intravitreal injection. Anti-VEGF may directly obstruct aqueous outflow via the trabecular mechwork, the uveoscleral pathway or Schlemm canal<sup id="cite_ref-tseng20_21-2" class="reference"><a href="#cite_note-tseng20-21">&#91;21&#93;</a></sup>. The drug or byproducts of pharmacologic compounding or storage may physically block the outflow system or damage the cells of the trabecular meswork; and repeated intravitreal injection may lead to chronic inflammation or trabeculitis which could also contribute to sustained ocular hypertension<sup id="cite_ref-tseng20_21-3" class="reference"><a href="#cite_note-tseng20-21">&#91;21&#93;</a></sup>.  Basic science studies support that long-term sustained elevation in IOP is due to a decrease in tonographic outflow facility.<sup id="cite_ref-23" class="reference"><a href="#cite_note-23">&#91;23&#93;</a></sup> 
</p>
<h2><span class="mw-headline" id="Management_4">Management</span></h2>
<p>As the half life of intravitreal ranibizumab is approximately 3 days, the elevated IOP seen following intravitreal injection is usually transient<sup id="cite_ref-tseng20_21-4" class="reference"><a href="#cite_note-tseng20-21">&#91;21&#93;</a></sup>. Reducing the frequency of intravitreal anti-VEGF treatment by assessing treatment efficacy with OCT also appears to reduce the risk of sustained IOP elevation. In a recent study, Tseng et al.<sup id="cite_ref-tseng20_21-5" class="reference"><a href="#cite_note-tseng20-21">&#91;21&#93;</a></sup> reported on 19 eyes in which the IOP continued to rise during continued anti-VEGF therapy; antiglaucoma treatment included topical therapy (19 out of 19 patients), changing to OCT- guided "as needed" (PRN) dosing (6 out of 19 patients), laser trabeculoplasty  (3 out of 19 patients), and glaucoma filtration surgery (5 out of 19 patients).  
</p>
<h1><span id="Glaucoma_following_intravitreal_triamcinolone_acetonide_injection_(IVTA):"></span><span class="mw-headline" id="Glaucoma_following_intravitreal_triamcinolone_acetonide_injection_.28IVTA.29:">Glaucoma following intravitreal triamcinolone acetonide injection (IVTA):</span></h1>
<h2><span class="mw-headline" id="Incidence_5">Incidence</span></h2>
<p>IVTA has been shown to have a high incidence of IOP elevation following a single intravitreal injection. Approximately 40% of patients can develop an IOP greater than 24 mm Hg at 6 months following 4 mg of IVTA injection<sup id="cite_ref-smithen21_24-0" class="reference"><a href="#cite_note-smithen21-24">&#91;24&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Risk_factors_5">Risk factors</span></h2>
<p>There are several factors that may increase the risk for steroid-induced ocular hypertension. A review of the literature by Jones et al.<sup id="cite_ref-jones22_25-0" class="reference"><a href="#cite_note-jones22-25">&#91;25&#93;</a></sup> listed the following as predisposing risk factors: pre-existing primary open angle glaucoma or ocular hypertension; a family history of glaucoma in a first-degree relative; age (which appears to have a bimodal distribution peaking at age 6 and old age at the highest risk); connective tissue disease; type-1 diabetes; and high myopia. 
</p>
<h2><span class="mw-headline" id="Pathophysiology_5">Pathophysiology</span></h2>
<p>Corticosteroids induce ocular hypertension by increasing the resistance of aqueous outflow through several mechanisms. Jones et al.<sup id="cite_ref-jones22_25-1" class="reference"><a href="#cite_note-jones22-25">&#91;25&#93;</a></sup> have summarized these mechanisms into three categories:&#160; induced physical and mechanical changes in the microstructure of the trabecular meshwork thus impeding outflow of aqueous humor; increased deposition of substances in the trabecular meshwork which reduces outflow; decreased breakdown of substances in the trabecular meshwork by inhibiting proteases and trabecular meshwork endothelial cell phagocytosis. These three mechanisms act together to increase aqueous outflow resistance, thereby increasing IOP. 
</p>
<h2><span class="mw-headline" id="Management_5">Management</span></h2>
<p>Following intravitreal injection of triamcinolone acetonide, patients should be followed closely, especially those with risk factors. Jones et al.<sup id="cite_ref-jones22_25-2" class="reference"><a href="#cite_note-jones22-25">&#91;25&#93;</a></sup> suggest that patients with high risk of developing glaucoma should have their IOP checked 1 day post-injection, 1 week post-injection and 6 months thereafter, though others advocate for more frequent follow up. Initial management includes discontinuing steroid use if possible and initiating glaucoma medications. One study suggested that triamcinolone induced IOP elevation may last up to 9 months or longer after an intravitreal injection<sup id="cite_ref-jonas23_26-0" class="reference"><a href="#cite_note-jonas23-26">&#91;26&#93;</a></sup>; therefore the risks of IOP elevation must be considered seriously before IVTA use in high-risk patients.&#160; Treatment with antiglaucoma medications is usually sufficient in controlling IOP;&#160;&#160; in the majority of patients, IOP returns to baseline and glaucoma medications can be discontinued within 6 months from the time of injection<sup id="cite_ref-jonas24_27-0" class="reference"><a href="#cite_note-jonas24-27">&#91;27&#93;</a></sup>. Agrawal, et al. found that trabeculectomy is needed to control IOP in less than 2% of cases;&#160; both standard trabeculectomy as well as trabeculectomy combined with vitrectomy to remove intravitreal&#160; traimcinolone acetonide&#160; have been shown to be successful in controlling IOP<sup id="cite_ref-agrawal25_28-0" class="reference"><a href="#cite_note-agrawal25-28">&#91;28&#93;</a></sup>.  
</p>
<h1><span class="mw-headline" id="Glaucoma_following_use_of_silicone_oil">Glaucoma following use of silicone oil</span></h1>
<h2><span class="mw-headline" id="Incidence_6">Incidence</span></h2>
<p>Secondary glaucoma is a known complication of the use of silicone oil tampanode in the treatment of complicated retinal detachment. The incidence varies widely among studies, ranging from 2.2% to 56%, with recent studies demonstrating a lower prevalence than previously reported<sup id="cite_ref-decorral26_29-0" class="reference"><a href="#cite_note-decorral26-29">&#91;29&#93;</a></sup> <sup id="cite_ref-honavar27_30-0" class="reference"><a href="#cite_note-honavar27-30">&#91;30&#93;</a></sup>. However, most studies agree that a high percentage of patients do have a secondary IOP elevation that is often mild and transient, with a small percentage of patients developing chronic glaucoma. 
</p>
<h2><span class="mw-headline" id="Risk_factors_6">Risk factors</span></h2>
<p>Although the risk factors for development of IOP elevation remain unclear, several prognostic factors have been evaluated by a number of studies. Risk factors include pre-existing glaucoma, history of diabetes mellitus, and aphakia<sup id="cite_ref-gedde2_2-6" class="reference"><a href="#cite_note-gedde2-2">&#91;2&#93;</a></sup>. Among patients with CMV retinitis, the incidence of elevated IOP is rare, which is attributed to the diminished inflammatory response due to the underlying immune-compromised state. The quantity of emulsified silicone oil in the anterior chamber as well as the use of heavy tamponade agents has been shown to be associated with a significant IOP rise postoperatively<sup id="cite_ref-ichhpujani4_4-2" class="reference"><a href="#cite_note-ichhpujani4-4">&#91;4&#93;</a></sup>.  
</p>
<h2><span class="mw-headline" id="Pathophysiology_6">Pathophysiology</span></h2>
<p>There are several proposed mechanisms of silicone oil related glaucoma which may be divided into two groups: early postoperative IOP elevation and late-onset glaucoma. The mechanisms of early IOP rise may be due to pupillary block, inflammation, pre-existing glaucoma, and/or migration of silicone oil into the anterior chamber with resulting mechanical impediment to filtration. Possible mechanisms of late-onset glaucoma are infiltration of the trabecular meshwork by silicone bubbles, chronic inflammation, synechial angle closure, rubeosis iridis, migration of emulsified and nonemulsified silicone oil into the anterior chamber, and/or idiopathic open angle glaucoma4. 
</p>
<h2><span class="mw-headline" id="Management_6">Management</span></h2>
<p>Treatment of silicone oil associated glaucoma depends largely on the clinical presentation and the mechanism of IOP elevation. Management may include topical medications alone or in conjunction with surgical and/or laser interventions. Topical medical therapy including cycloplegics, corticosteroids, beta-blockers and prostaglandin analogues has been shown to result in successful control of IOP in 30-78% of patients<sup id="cite_ref-honavar27_30-1" class="reference"><a href="#cite_note-honavar27-30">&#91;30&#93;</a></sup><sup id="cite_ref-aljazzaf28_31-0" class="reference"><a href="#cite_note-aljazzaf28-31">&#91;31&#93;</a></sup>. Prophylactic peripheral iridectomy at the 6-oâ€™clock position has lowered the incidence of pupillary block caused by floating silicone oil. However, peripheral iridectomies may close in up to 11-32% of cases and need to be reopened or a new iridotomy created to prevent the development of pupil block<sup id="cite_ref-ichhpujani4_4-3" class="reference"><a href="#cite_note-ichhpujani4-4">&#91;4&#93;</a></sup>. Transcleral cyclophotocoagulation may be an option when the risk of redetachment with silicone oil removal is unacceptable, or in eyes with poor visual potential due to its risk of visual loss. Early silicone oil removal may result in improvement in IOP control by reversing mechanical trabecular blockage; however silicone oil removal must be weighed against the risk of retinal detachment. One study has shown that 93.4% of patients had normalization of IOP after removal of silicone oil tamponade, whereas another study reported that elevated IOP persisted in all eyes even after silicone oil removal<sup id="cite_ref-jonas29_32-0" class="reference"><a href="#cite_note-jonas29-32">&#91;32&#93;</a></sup> <sup id="cite_ref-flaxel30_33-0" class="reference"><a href="#cite_note-flaxel30-33">&#91;33&#93;</a></sup>. A persistent IOP rise after silicone oil removal is thought to be due to inflammation and edema of the trabecular meshwork, as well as the obstruction of meshwork by small silicone oil droplets4. Glaucoma surgery and drainage devices may be considered in patients with refractory glaucoma, as well as patients with complete synechial angle closure since silicone oil removal alone is unlikely to be beneficial in these cases. However, standard filtration surgery may be technically difficult due to scarring of the conjunctiva from prior retinal surgery, and is associated with a poor prognosis and increased risk of complications. An inferiorly placed glaucoma drainage implant may be a useful alternative; in one study, the success rate of inferotemporally placed Ahmed glaucoma shunts was 86% at 6 months and 76% at one year after implantation<sup id="cite_ref-aljazzaf28_31-1" class="reference"><a href="#cite_note-aljazzaf28-31">&#91;31&#93;</a></sup>.  
</p>
<h1><span class="mw-headline" id="Glaucoma_following_intravitreal_gas">Glaucoma following intravitreal gas</span></h1>
<h2><span class="mw-headline" id="Incidence_7">Incidence</span></h2>
<p>Intraocular gases, specifically sulfur hexafluoride (SF6) and perflouropropane (C3F8), are frequently used for retinal tamponade due to their innate properties; they are expansile and have a long resorption time, which provides greater surface tension and allows more time for choroidal-retinal adhesions. However, these properties may also result in IOP elevation.<sup id="cite_ref-abrams31_34-0" class="reference"><a href="#cite_note-abrams31-34">&#91;34&#93;</a></sup> The incidence of IOP rise following intravitreal SF6 and C3F8 injection has been estimated to range from 6.1% to 67%, and 18% to 59%, respectively<sup id="cite_ref-thessg32_35-0" class="reference"><a href="#cite_note-thessg32-35">&#91;35&#93;</a></sup> <sup id="cite_ref-chang33_36-0" class="reference"><a href="#cite_note-chang33-36">&#91;36&#93;</a></sup> <sup id="cite_ref-thessg34_37-0" class="reference"><a href="#cite_note-thessg34-37">&#91;37&#93;</a></sup>. The higher incidence associated with C3F8 is thought to be related to its greater maximal volume expansion (4 times maximal volume expansion for C3F8 compared to 2 times maximal volume expansion for SF6), as well as longer intraocular longevity (55-65 days for C3F8 compared to 10-14 days for SF6)<sup id="cite_ref-gedde2_2-7" class="reference"><a href="#cite_note-gedde2-2">&#91;2&#93;</a></sup>.
</p>
<h2><span class="mw-headline" id="Risk_factors_7">Risk factors</span></h2>
<p>There are several variables associated with IOP elevation; higher concentrations of the expansile gas, use of C3F8, older patient age, intraoperative use of photocoagulation, concurrent lensectomy or placement of circumferential scleral buckle, and fibrinous anterior chamber exudates<sup id="cite_ref-costarides1_1-5" class="reference"><a href="#cite_note-costarides1-1">&#91;1&#93;</a></sup>.  
</p>
<h2><span class="mw-headline" id="Pathophysiology_7">Pathophysiology</span></h2>
<p>Secondary glaucoma following intravitreal gas injection may be due to both open-angle and closed-angle mechanisms. Open-angle mechanisms occur when expansion of the intraocular gas bubble exceeds the rate of outflow of intraocular fluid, or when the intraocular gas volume causes posterior chamber pressure build-up without angle-closure. Secondary closed-angle glaucoma results from anterior displacement of the lens-iris diaphragm causing iridocorneal apposition as a result of either pupillary block or non-pupillary block mechanisms<sup id="cite_ref-costarides1_1-6" class="reference"><a href="#cite_note-costarides1-1">&#91;1&#93;</a></sup><sup id="cite_ref-han3_3-12" class="reference"><a href="#cite_note-han3-3">&#91;3&#93;</a></sup>. 
</p>
<h2><span class="mw-headline" id="Management_7">Management</span></h2>
<p>Intraocular pressure should be assessed by using the Goldmann applanation tonometer or Perkins tonometer. Pneumatic tonometers and high displacement tonometers may significantly underestimate the IOP due to compressibility of the intraocular gas<sup id="cite_ref-costarides1_1-7" class="reference"><a href="#cite_note-costarides1-1">&#91;1&#93;</a></sup>. Patient education is an essential part of management following intravitreal gas injection. The importance of maintaining a prone position must be emphasized to prevent anterior displacement of the lens-iris diaphragm. In addition, the patient should be strictly instructed to abstain from air travel until complete intraocular gas bubble resorption due to rapid expansion of the intravitreal gas volume with diminished atmospheric pressure. Elevations in IOP usually occur within the first 24 hours, and mild elevations in IOP frequently respond to topical aqueous suppressants or oral carbonic anhydrase inhibitors within 24 to 72 hours. If IOP rise is severe, it may be necessary to aspirate a potion of the intraocular gas to normalize IOP. Similar to silicone oil associated glaucoma, laser iridotomy may be beneficial in cases of pupillary block, and glaucoma drainage implantation may be a better surgical option compared to traditional filtering surgery if there is extensive to conjunctival scarring<sup id="cite_ref-costarides1_1-8" class="reference"><a href="#cite_note-costarides1-1">&#91;1&#93;</a></sup><sup id="cite_ref-gedde2_2-8" class="reference"><a href="#cite_note-gedde2-2">&#91;2&#93;</a></sup>.  
</p>
<h1><span class="mw-headline" id="Conclusion">Conclusion</span></h1>
<p>Secondary glaucoma is a well known complication following various retinal procedures. The mechanism can be open angle, closed angle or both. Most cases of secondary glaucoma can be management medically, with a small proportion of patients requiring laser and/or surgical intervention to achieve IOP control. 
</p>
<h1><span class="mw-headline" id="Additional_Resources">Additional Resources</span></h1>
<ul><li>Gudgel DT,  Iwach AG. <a rel="nofollow" class="external text" href="https://www.aao.org/eye-health/anatomy/eye-pressure-list">Eye Pressure</a>. American Academy of Ophthalmology. EyeSmart<sup>Â®</sup> Eye health. <a rel="nofollow" class="external free" href="https://www.aao.org/eye-health/anatomy/eye-pressure-list">https://www.aao.org/eye-health/anatomy/eye-pressure-list</a>. Accessed March 12, 2019.</li></ul>
<h1><span class="mw-headline" id="References">References</span></h1>
<div class="mw-references-wrap mw-references-columns"><ol class="references">
<li id="cite_note-costarides1-1"><span class="mw-cite-backlink">â†‘ <sup><a href="#cite_ref-costarides1_1-0">1.0</a></sup> <sup><a href="#cite_ref-costarides1_1-1">1.1</a></sup> <sup><a href="#cite_ref-costarides1_1-2">1.2</a></sup> <sup><a href="#cite_ref-costarides1_1-3">1.3</a></sup> <sup><a href="#cite_ref-costarides1_1-4">1.4</a></sup> <sup><a href="#cite_ref-costarides1_1-5">1.5</a></sup> <sup><a href="#cite_ref-costarides1_1-6">1.6</a></sup> <sup><a href="#cite_ref-costarides1_1-7">1.7</a></sup> <sup><a href="#cite_ref-costarides1_1-8">1.8</a></sup></span> <span class="reference-text">Costarides AP, Alabata P, Bergstrom C. Elevated intraocular pressure following vitreoretinal surgery. Ophthalmol Clin N Am. 2004; 17(4):507-512. </span>
</li>
<li id="cite_note-gedde2-2"><span class="mw-cite-backlink">â†‘ <sup><a href="#cite_ref-gedde2_2-0">2.0</a></sup> <sup><a href="#cite_ref-gedde2_2-1">2.1</a></sup> <sup><a href="#cite_ref-gedde2_2-2">2.2</a></sup> <sup><a href="#cite_ref-gedde2_2-3">2.3</a></sup> <sup><a href="#cite_ref-gedde2_2-4">2.4</a></sup> <sup><a href="#cite_ref-gedde2_2-5">2.5</a></sup> <sup><a href="#cite_ref-gedde2_2-6">2.6</a></sup> <sup><a href="#cite_ref-gedde2_2-7">2.7</a></sup> <sup><a href="#cite_ref-gedde2_2-8">2.8</a></sup></span> <span class="reference-text">Gedde SJ. Management of glaucoma after retinal detachment surgery. Curr Opin Ophthalmol. 2002;13(2):103-9. </span>
</li>
<li id="cite_note-han3-3"><span class="mw-cite-backlink">â†‘ <sup><a href="#cite_ref-han3_3-0">3.00</a></sup> <sup><a href="#cite_ref-han3_3-1">3.01</a></sup> <sup><a href="#cite_ref-han3_3-2">3.02</a></sup> <sup><a href="#cite_ref-han3_3-3">3.03</a></sup> <sup><a href="#cite_ref-han3_3-4">3.04</a></sup> <sup><a href="#cite_ref-han3_3-5">3.05</a></sup> <sup><a href="#cite_ref-han3_3-6">3.06</a></sup> <sup><a href="#cite_ref-han3_3-7">3.07</a></sup> <sup><a href="#cite_ref-han3_3-8">3.08</a></sup> <sup><a href="#cite_ref-han3_3-9">3.09</a></sup> <sup><a href="#cite_ref-han3_3-10">3.10</a></sup> <sup><a href="#cite_ref-han3_3-11">3.11</a></sup> <sup><a href="#cite_ref-han3_3-12">3.12</a></sup></span> <span class="reference-text">Han DP, Lewis H, Lambrou FH Jr, et al. Mechanisms of intraocular pressure elevation after pars plana vitrectomy. Ophthalmology. 1989;96:1357. </span>
</li>
<li id="cite_note-ichhpujani4-4"><span class="mw-cite-backlink">â†‘ <sup><a href="#cite_ref-ichhpujani4_4-0">4.0</a></sup> <sup><a href="#cite_ref-ichhpujani4_4-1">4.1</a></sup> <sup><a href="#cite_ref-ichhpujani4_4-2">4.2</a></sup> <sup><a href="#cite_ref-ichhpujani4_4-3">4.3</a></sup></span> <span class="reference-text">Ichhpujani P, Jindal A, Katz JL. Silicone oil induced glaucoma: a review. Graefes Arch Clin Exp Ophthalmol. 2009;247(12):1585-1593. </span>
</li>
<li id="cite_note-faulborn5-5"><span class="mw-cite-backlink"><a href="#cite_ref-faulborn5_5-0">â†‘</a></span> <span class="reference-text">Faulborn J, Conway BP, Machemer R. Surgical complications of pars plana vitreous surgery. Ophthalmology. 1978;85:116. </span>
</li>
<li id="cite_note-aaberg6-6"><span class="mw-cite-backlink"><a href="#cite_ref-aaberg6_6-0">â†‘</a></span> <span class="reference-text">Aaberg TM, Van Horn DL. Late complications of pars plana vitreous surgery. Ophthalmology. 1978:85:126 </span>
</li>
<li id="cite_note-ghartey7-7"><span class="mw-cite-backlink"><a href="#cite_ref-ghartey7_7-0">â†‘</a></span> <span class="reference-text">Ghartey KN, Teolentine FI, Freeman HM, et al. Close vitreous surgery. XVII. Results and complications of pars plana vitrectomy. Arch Ophthalmol. 1980:98:1248. </span>
</li>
<li id="cite_note-lalezary8-8"><span class="mw-cite-backlink"><a href="#cite_ref-lalezary8_8-0">â†‘</a></span> <span class="reference-text">Lalezary M, Kim SJ, Jiramongkolchai K, Recchia FM, Agarwal A, Sternberg P Jr. Long-term trends in intraocular pressure after pars plana vitrectomy. Retina. 2011;31(4):679-685. </span>
</li>
<li id="cite_note-9"><span class="mw-cite-backlink"><a href="#cite_ref-9">â†‘</a></span> <span class="reference-text">Mansukhani SA, Barkmeier AJ, Bakri SJ, et al. The Risk of Primary Open-Angle Glaucoma Following Vitreoretinal Surgery - A population-based Study. Am J Ophthalmol. 2018;193:143-155.</span>
</li>
<li id="cite_note-tranos9-10"><span class="mw-cite-backlink"><a href="#cite_ref-tranos9_10-0">â†‘</a></span> <span class="reference-text">Tranos P, Bhar G, Little B. Postoperative intraocular pressure spikes: the need to treat. Eye(Lond). 2004; 18(7):673-9. </span>
</li>
<li id="cite_note-lewis10-11"><span class="mw-cite-backlink"><a href="#cite_ref-lewis10_11-0">â†‘</a></span> <span class="reference-text">Lewis H, Han D, Wiliams GA. Management of fibrin papillary-block glaucoma after pars plana vitrectomy with intravitreal gas injection. Am J Opthalmol. 1987;103:180. </span>
</li>
<li id="cite_note-jaffe11-12"><span class="mw-cite-backlink"><a href="#cite_ref-jaffe11_12-0">â†‘</a></span> <span class="reference-text">Jaffe GJ, Lewis H, Han DP, et al. Treatment of postvitrectomy fibrin papillary block with tissue plasminogen activator. Am J Ophthalmol. 1989;108:170. </span>
</li>
<li id="cite_note-sebestyen12-13"><span class="mw-cite-backlink"><a href="#cite_ref-sebestyen12_13-0">â†‘</a></span> <span class="reference-text">Sebestyen JG, Schepens CL, Rosenthal ML. Retinal detachment and glaucoma. I. Tonometric and gonioscopic study of 160 cases. Arch Ophthalmol. 1962;67:736-745.</span>
</li>
<li id="cite_note-perez13-14"><span class="mw-cite-backlink"><a href="#cite_ref-perez13_14-0">â†‘</a></span> <span class="reference-text">Perez RN, Phelps CD, Burton TC. Angle-closure glaucoma following scleral buckling operations. Trans Am Acad Ophthalmol Otolaryngol. 1976;81:247-252. </span>
</li>
<li id="cite_note-hartley14-15"><span class="mw-cite-backlink"><a href="#cite_ref-hartley14_15-0">â†‘</a></span> <span class="reference-text">Hartley RE, Marsh RJ. Anterior chamber depth changes after retinal detachment. Br J Opthalmol. 1973;57:546-550. </span>
</li>
<li id="cite_note-sidoti15-16"><span class="mw-cite-backlink"><a href="#cite_ref-sidoti15_16-0">â†‘</a></span> <span class="reference-text">Sidoti PA, Minckler DS, Baerveldt G, et al. Aqueous tube shunt to a pre-existing episcleral encircling element in the treatment of complicated glaucomas. Ophthalmology. 1994;101:1036-1043. </span>
</li>
<li id="cite_note-tsai16-17"><span class="mw-cite-backlink">â†‘ <sup><a href="#cite_ref-tsai16_17-0">17.0</a></sup> <sup><a href="#cite_ref-tsai16_17-1">17.1</a></sup> <sup><a href="#cite_ref-tsai16_17-2">17.2</a></sup> <sup><a href="#cite_ref-tsai16_17-3">17.3</a></sup> <sup><a href="#cite_ref-tsai16_17-4">17.4</a></sup></span> <span class="reference-text">Tsai JC, Lee MB, WuDunn D, Dacey MP, Choi JC, Minckler DS. Incidence of Acute intraocular pressure elevation after panretinal photocoagulation. J Glaucoma. 1995;4(1):45-8. </span>
</li>
<li id="cite_note-blondeau17-18"><span class="mw-cite-backlink">â†‘ <sup><a href="#cite_ref-blondeau17_18-0">18.0</a></sup> <sup><a href="#cite_ref-blondeau17_18-1">18.1</a></sup> <sup><a href="#cite_ref-blondeau17_18-2">18.2</a></sup> <sup><a href="#cite_ref-blondeau17_18-3">18.3</a></sup></span> <span class="reference-text">Blondeau P, Pavan PR, Phelps CD. Acute pressure elevation following panretinal photocoagulation. Arch Ophthalmol. 1981;99(7):1239-41. </span>
</li>
<li id="cite_note-adelman18-19"><span class="mw-cite-backlink"><a href="#cite_ref-adelman18_19-0">â†‘</a></span> <span class="reference-text">Adelman RA, Zheng Q, Mayer HR. Persistent ocular hypertension following intravitreal bevacizumab and ranibizumab injections. J Ocul Pharmacol Ther. 2010;26:105-110. </span>
</li>
<li id="cite_note-good19-20"><span class="mw-cite-backlink">â†‘ <sup><a href="#cite_ref-good19_20-0">20.0</a></sup> <sup><a href="#cite_ref-good19_20-1">20.1</a></sup></span> <span class="reference-text">Good TJ, Kimura AE, Wong LJ, et al. Sustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents. Br J Ophthalmol. 2010;95(8): 1111-4. </span>
</li>
<li id="cite_note-tseng20-21"><span class="mw-cite-backlink">â†‘ <sup><a href="#cite_ref-tseng20_21-0">21.0</a></sup> <sup><a href="#cite_ref-tseng20_21-1">21.1</a></sup> <sup><a href="#cite_ref-tseng20_21-2">21.2</a></sup> <sup><a href="#cite_ref-tseng20_21-3">21.3</a></sup> <sup><a href="#cite_ref-tseng20_21-4">21.4</a></sup> <sup><a href="#cite_ref-tseng20_21-5">21.5</a></sup></span> <span class="reference-text">Tseng JJ, Vance SK, Della Torre KE, Mendonca LS, Cooney MJ, Klancnik JM, Sorenson JA, Freund KB. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma. 2011;00:000-000. Accessed July 17, 2011. doi: 10.1097/IJG.0b013e31820d7d19. </span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><a href="#cite_ref-22">â†‘</a></span> <span class="reference-text">Aref AA, Scott IU, VanVeldhuisen PC, et al. Intraocular Pressure-Related Events After Anti-Vascular Endothelial Growth Factor Therapy for Macular Edema Due to Central Retinal Vein Occlusion or Hemiretinal Vein Occlusion: SCORE2 Report 16 on a Secondary Analysis of a Randomized Clinical Trial. JAMA Ophthalmol. 2021.</span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><a href="#cite_ref-23">â†‘</a></span> <span class="reference-text">Wen JC&lt; Reina-Torres E, Sherwood JM, et al. Intravitreal Anti-VEGF injections reduce aqueous outflow facility in patients with neovasuclar age-related macular degeneration. Invest Ophthalmol Vis Sci. 2017;58:1893-1898.</span>
</li>
<li id="cite_note-smithen21-24"><span class="mw-cite-backlink"><a href="#cite_ref-smithen21_24-0">â†‘</a></span> <span class="reference-text">Smithen LM, Ober MD, Maranan L, Spaide RF. Intravitreal triamcinolone acetonide and intraocular pressure. Am J Ophthalmol. 2004;138:740-743. </span>
</li>
<li id="cite_note-jones22-25"><span class="mw-cite-backlink">â†‘ <sup><a href="#cite_ref-jones22_25-0">25.0</a></sup> <sup><a href="#cite_ref-jones22_25-1">25.1</a></sup> <sup><a href="#cite_ref-jones22_25-2">25.2</a></sup></span> <span class="reference-text">Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17(2):163-7. </span>
</li>
<li id="cite_note-jonas23-26"><span class="mw-cite-backlink"><a href="#cite_ref-jonas23_26-0">â†‘</a></span> <span class="reference-text">Jonas JB, Kreissig I, Degenring R. Secondary chronic open-angle glaucoma after intravitreal triamcinolone acetonide. Arch Ophthalmol. 2003;121:729-730. </span>
</li>
<li id="cite_note-jonas24-27"><span class="mw-cite-backlink"><a href="#cite_ref-jonas24_27-0">â†‘</a></span> <span class="reference-text">Jonas JB, Degenrigh RF, Kreissig I, et al. Intraocular pressure elevation after intravitreal triamcinolone acetonide injection. Ophthalmology. 2005;112:593-598. </span>
</li>
<li id="cite_note-agrawal25-28"><span class="mw-cite-backlink"><a href="#cite_ref-agrawal25_28-0">â†‘</a></span> <span class="reference-text">Agrawal S, Agrawal J, Agrawal T. Management of intractable glaucoma following intravitreal triamcinolone acetonide. Am J Ophthalmol. 2004;138:286-287. </span>
</li>
<li id="cite_note-decorral26-29"><span class="mw-cite-backlink"><a href="#cite_ref-decorral26_29-0">â†‘</a></span> <span class="reference-text">De Corral LR, Cohen SB, Peyman GA. Effect of intravitreal silicone oil on intraocular pressure. Ophthalmic Surg. 1987;18:446-449. </span>
</li>
<li id="cite_note-honavar27-30"><span class="mw-cite-backlink">â†‘ <sup><a href="#cite_ref-honavar27_30-0">30.0</a></sup> <sup><a href="#cite_ref-honavar27_30-1">30.1</a></sup></span> <span class="reference-text">Honavar SG, Goyal M, Majji AB et al. Glaucoma after pars plana vitrectomy and silicone oil injection for complicated retinal detachments. Ophthalmology. 1999; 10:169-167. </span>
</li>
<li id="cite_note-aljazzaf28-31"><span class="mw-cite-backlink">â†‘ <sup><a href="#cite_ref-aljazzaf28_31-0">31.0</a></sup> <sup><a href="#cite_ref-aljazzaf28_31-1">31.1</a></sup></span> <span class="reference-text">Al-Jazzaf AM, Netland PA, Chales S. Incidence and management of elevated intraocular pressure after silicone oil injection. J Glaucoma. 2005;14(1):40-46. </span>
</li>
<li id="cite_note-jonas29-32"><span class="mw-cite-backlink"><a href="#cite_ref-jonas29_32-0">â†‘</a></span> <span class="reference-text">Jonas JB, Knorr HL, Rank RM, Budde WM. Intraocular pressure and silicone oil endotamponade. J Glaucoma. 2001;10:102-108. </span>
</li>
<li id="cite_note-flaxel30-33"><span class="mw-cite-backlink"><a href="#cite_ref-flaxel30_33-0">â†‘</a></span> <span class="reference-text">Flaxel CJ, Mitchell SM, Aylward GW. Visual outcome after silicone oil removal and recurrent retinal detachment repair. Eye. 2000;14:834-838. </span>
</li>
<li id="cite_note-abrams31-34"><span class="mw-cite-backlink"><a href="#cite_ref-abrams31_34-0">â†‘</a></span> <span class="reference-text">Abrams GW, Swanson DE, Sabates WI. The results of sulfur hexaflouride gas in vitreous surgery. Am J Ophthalmol. 1982;94:165-171 </span>
</li>
<li id="cite_note-thessg32-35"><span class="mw-cite-backlink"><a href="#cite_ref-thessg32_35-0">â†‘</a></span> <span class="reference-text">The Silicone Study Group. Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: Results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol. 1992;110:770-779. </span>
</li>
<li id="cite_note-chang33-36"><span class="mw-cite-backlink"><a href="#cite_ref-chang33_36-0">â†‘</a></span> <span class="reference-text">Chang S, Lincoff HA, Coleman D, et al. Perflourocarbon gases in vitreous surgery. Ophthalmology. 1985;92:651-656. </span>
</li>
<li id="cite_note-thessg34-37"><span class="mw-cite-backlink"><a href="#cite_ref-thessg34_37-0">â†‘</a></span> <span class="reference-text">The Silicone Study Group. Vitrectomy with silicone oil or perflouropropane gas in eyes with severe proliferative vitreoretinopathy: Results of a randomized clinical trial. Silicone Study Report 2. Arch Ophthalmol. 1992;110:780-792.</span>
</li>
</ol></div>
<!-- 
NewPP limit report
Cached time: 20230306035152
Cache expiry: 86400
Dynamic content: false
Complications: [my_variables_no_cache]
[SMW] Inâ€text annotation parser time: 0.009 seconds
CPU time usage: 0.295 seconds
Real time usage: 1.479 seconds
Preprocessor visited node count: 1158/1000000
Postâ€expand include size: 5862/2097152 bytes
Template argument size: 1168/2097152 bytes
Highest expansion depth: 11/40
Expensive parser function count: 0/100
Unstrip recursion depth: 0/20
Unstrip postâ€expand size: 23168/5000000 bytes
-->
<!--
Transclusion expansion time report (%,ms,calls,template)
100.00%  385.720      1 Template:Article
100.00%  385.720      1 -total
 85.11%  328.271      4 Template:Infobox_section
 30.16%  116.329      6 Template:UserLookup
  5.57%   21.468      1 Template:Review_expired
  2.71%   10.469      1 Template:Infobox_end
  0.93%    3.590      1 Template:Get_active_contest
  0.24%    0.918      1 Template:Infobox_begin
-->
</div></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://eyewiki.org/w/index.php?title=Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures&amp;oldid=87673">https://eyewiki.org/w/index.php?title=Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures&amp;oldid=87673</a>"</div>

						<!-- end body text -->
						<!-- data blocks which should go somewhere after the body text, but not before the catlinks block-->
						<div id='mw-data-after-content'>
	<div class="mw-cookiewarning-container"><div class="mw-cookiewarning-text"><span>The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.</span></div><form method="POST"><div class='oo-ui-layout oo-ui-horizontalLayout'><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-progressive oo-ui-buttonWidget'><a role='button' tabindex='0' aria-disabled='false' href='https://www.aao.org/privacy-policy' rel='nofollow' class='oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-progressive'></span><span class='oo-ui-labelElement-label'>Learn more</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-progressive'></span></a></span><span aria-disabled='false' class='oo-ui-widget oo-ui-widget-enabled oo-ui-inputWidget oo-ui-buttonElement oo-ui-buttonElement-framed oo-ui-labelElement oo-ui-flaggedElement-primary oo-ui-flaggedElement-progressive oo-ui-buttonInputWidget'><button type='submit' tabindex='0' aria-disabled='false' name='disablecookiewarning' value='OK' class='oo-ui-inputWidget-input oo-ui-buttonElement-button'><span class='oo-ui-iconElement-icon oo-ui-iconElement-noIcon oo-ui-image-invert'></span><span class='oo-ui-labelElement-label'>Accept</span><span class='oo-ui-indicatorElement-indicator oo-ui-indicatorElement-noIndicator oo-ui-image-invert'></span></button></span></div></form></div>
</div>

					</div>
					<!-- category links -->
					<div id="catlinks" class="catlinks" data-mw="interface"><div id="mw-normal-catlinks" class="mw-normal-catlinks"><a href="/Special:Categories" title="Special:Categories">Categories</a>: <ul><li><a href="/Category:Articles" title="Category:Articles">Articles</a></li><li><a href="/Category:Glaucoma" title="Category:Glaucoma">Glaucoma</a></li></ul></div></div>
				</div>
			</div>
		</div>
	</div>
	<div class="mb-2 mt-4 footer container">
		<div class="row">
			<div class="col">
				<!-- navigation bar -->
				<nav class="p-navbar not-collapsible small mb-2" role="navigation" id="mw-navigation-hbpzyttxv7">
					<div class="navbar-nav">
					<!-- toolbox -->
					<div id="t-whatlinkshere" class="nav-item"><a href="/Special:WhatLinksHere/Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures" title="A list of all wiki pages that link here [j]" accesskey="j" class="nav-link t-whatlinkshere">What links here</a></div>
					<div id="t-recentchangeslinked" class="nav-item"><a href="/Special:RecentChangesLinked/Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures" rel="nofollow" title="Recent changes in pages linked from this page [k]" accesskey="k" class="nav-link t-recentchangeslinked">Related changes</a></div>
					<div id="t-specialpages" class="nav-item"><a href="/Special:SpecialPages" title="A list of all special pages [q]" accesskey="q" class="nav-link t-specialpages">Special pages</a></div>
					<div id="t-print" class="nav-item"><a href="javascript:print();" rel="alternate" title="Printable version of this page [p]" accesskey="p" class="nav-link t-print">Printable version</a></div>
					<div id="t-permalink" class="nav-item"><a href="/w/index.php?title=Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures&amp;oldid=87673" title="Permanent link to this revision of the page" class="nav-link t-permalink">Permanent link</a></div>
					<div id="t-info" class="nav-item"><a href="/w/index.php?title=Elevated_Intraocular_Pressure_Associated_with_Retinal_Procedures&amp;action=info" title="More information about this page" class="nav-link t-info">Page information</a></div>
					</div>
				</nav>
			</div>
		</div>
		<div class="row">
			<div class="col">
				<!-- footer links -->
				<div id="footer-info" class="footer-info">
					<!-- info -->
					<div> This page was last edited on December 25, 2022, at 16:27.</div>
					<div>This page has been accessed 145,916 times.</div>
				</div>
				<!-- places -->
				<div id="footer-places" class="footer-places">
					<div><a href="/EyeWiki:Privacy_policy" title="EyeWiki:Privacy policy">Privacy policy</a></div>
					<div><a href="/EyeWiki:About" title="EyeWiki:About">About EyeWiki</a></div>
					<div><a href="/EyeWiki:General_disclaimer" title="EyeWiki:General disclaimer">Disclaimers</a></div>
				</div>
			</div>
			<div class="col">
				<!-- footer icons -->
				<div id="footer-icons" class="justify-content-end footer-icons">
					<!-- poweredby -->
					<div><a href="https://www.mediawiki.org/"><img src="/w/resources/assets/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" srcset="/w/resources/assets/poweredby_mediawiki_132x47.png 1.5x, /w/resources/assets/poweredby_mediawiki_176x62.png 2x" width="88" height="31" loading="lazy"/></a></div>
					<div><a href="https://www.semantic-mediawiki.org/wiki/Semantic_MediaWiki"><img src="data:image/png;base64,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" alt="Powered by Semantic MediaWiki" class="smw-footer" width="88" height="31" loading="lazy"/></a></div>
				</div>
			</div>
		</div>
	</div>
<script src="https://www.googletagmanager.com/gtag/js?id=UA-64665049-1" async=""></script><script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'UA-64665049-1', {});
</script>

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"smw":{"limitreport-intext-parsertime":0.009},"limitreport":{"cputime":"0.295","walltime":"1.479","ppvisitednodes":{"value":1158,"limit":1000000},"postexpandincludesize":{"value":5862,"limit":2097152},"templateargumentsize":{"value":1168,"limit":2097152},"expansiondepth":{"value":11,"limit":40},"expensivefunctioncount":{"value":0,"limit":100},"unstrip-depth":{"value":0,"limit":20},"unstrip-size":{"value":23168,"limit":5000000},"timingprofile":["100.00%  385.720      1 Template:Article","100.00%  385.720      1 -total"," 85.11%  328.271      4 Template:Infobox_section"," 30.16%  116.329      6 Template:UserLookup","  5.57%   21.468      1 Template:Review_expired","  2.71%   10.469      1 Template:Infobox_end","  0.93%    3.590      1 Template:Get_active_contest","  0.24%    0.918      1 Template:Infobox_begin"]},"cachereport":{"timestamp":"20230306035152","ttl":86400,"transientcontent":false}}});mw.config.set({"wgBackendResponseTime":2151});});</script></body>
</html>